Showing results (241-250 of 295) with videos related to

Sort By:
Pageof 30
Biorxiv : the Preprint Server for Biology|April 16, 2025
Selective targeting of oncogenic KRAS G12D using peptide nucleic acid oligomers attached to cell-penetrating peptidesJayati Mondal, Dennis Lam, Mary E Gerritsen, et al.
Science Advances|July 14, 2023
RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophyAntonio Cuevas-Navarro, Morgan Wagner, Richard Van, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 25, 2024
Determining KRAS4B-Targeting Compound Specificity by Top-Down Mass SpectrometryRobert A D'Ippolito, Grace M Scheidemantle, Dana Rabara, et al.
Progress in Transplantation (Aliso Viejo, Calif.)|November 16, 2023
Report From a Multidisciplinary Symposium on the Future of Living Kidney Donor TransplantationThomas G Peters, John J Fung, Janet Radcliffe-Richards, et al.
The Journal of Biological Chemistry|December 15, 2019
Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimerMukul Sherekar, Sae-Won Han, Rodolfo Ghirlando, et al.
The Journal of Biological Chemistry|June 5, 2025
Biophysical and structural analysis of KRAS switch-II pocket inhibitors reveals allele-specific binding constraintsPatrick Alexander, Albert H Chan, Dana Rabara, et al.
American Journal of Medical Genetics. Part A|January 19, 2010
What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiersJoseph L Kissil, Jaishri O Blakeley, Rosalie E Ferner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 28, 2019
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Chi-Heng Wu, Chen-Yen Yang, et al.
The Journal of Biological Chemistry|January 18, 2024
Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMRAlok K Sharma, Jun Pei, Yue Yang, et al.
Plos One|June 5, 2012
Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomasKeiko Shoji, Katsutoshi Oda, Tomoko Kashiyama, et al.
Pageof 30